Navigation Links
eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
Date:9/5/2008

- Novel system is the first to use rapid, automated DNA sequencing to

perform microbial 'fingerprinting'

NEW YORK, Sept. 5 /PRNewswire/ -- eGenomics, Inc., a leader in the development of state of the art genomic and informational systems for infectious disease control, announced today that the United States Patent and Trademark Office (USPTO) recently issued U.S. Patent no. 7,449,808, for key elements of its proprietary warning system for hospital infection control. The system "fingerprints" infection-causing bacteria using automated DNA sequencing, stores the resulting DNA sequences in a central database and analyzes the results using proprietary algorithms. The platform allows hospital infection control teams to monitor in "real time" the spread of specific harmful pathogens.

"The eGenomics System should be a major component of every hospitals' effort to monitor and prevent methycillin-resistant strains of Staphylococcus aureus (MRSA) infections," comments Barry Kreiswirth, the company's Chief Scientist. "In addition, the eGenomics platform works equally well on all Staphylococcus aureus -- MSSA and MRSA. We are in the process of expanding our monitoring system to work with other common nosocomial pathogens."

The eGenomics 'mapping' system differentiates clusters of related strains in order to identify a source or transmission vector. Importantly, the system can identify when strains are not related, effectively telling a hospital when they are and when they are not experiencing internal transmission problems.

"The eGenomics platform will allow infection control teams to monitor and prevent potential outbreaks as well as monitor random, non-outbreak events. It will allow us to focus our infection control efforts on the most critical areas," observed Dr. Brian Koll, the Chief of Infectious Disease at Beth Israel Medical Center in New York. "The eGenomics platform also allows us to monitor which MRSA strains are coming into the hospital from nursing homes and affiliated clinics."

The eGenomics system also complements the use of rapid MRSA tests that are being developed by other companies in the industry. "Incorporating the eGenomics system into existing and next generation rapid MRSA tests," adds Dr. Kreiswirth, "would provide hospitals with a system that guides containment and eradication efforts from first admission to final release. Such a combined system would add substantial capability to hospital infection control."

The eGenomics platform incorporates an ever growing proprietary library of over 6000 analyzed S. aureus strains, as well as other infectious organisms.

Dr. Kreiswirth noted that the eGenomics platform is expected to:

-- Reduce the chance of acquiring a nosocomial infection

-- Identify outbreaks and their sources before they become endemic

-- Identify non-outbreaks, allowing hospitals to avoid extreme and costly infection control measures

-- Direct more appropriate antibiotic usage, and thereby extend the effectiveness of existing antibiotics

-- Lower actual costs to control infections

-- Be faster and more accurate than comparable sub-speciation techniques such as Pulsed Field Gel Electrophoresis

-- Share "lessons learned" with participating institutions

-- Allow typically understaffed infection control teams to make infection control decisions based on qualitative data

The eGenomics system is currently being used in active surveillance programs at Beth Israel Medical Center New York (Continuum Health Care), Newark (NJ) Beth Israel Medical Center Newark, NJ (St. Barnabas Health Care System) and the VA Medical Center East Orange NJ. Scientists at the Centers for Disease Control and Prevention (CDC), Rockefeller University, Duke University Medical Center, Purdue University, The Institute for Genomic Research (TIGR) -- as well as research facilities in Australia, Japan, Canada, India, Portugal, The Netherlands, Germany, Mexico, Egypt and Scotland -- currently use the eGenomics software.

The patent, entitled "System and Method for Tracking and Controlling Infections," was written by Barry N. Kreiswirth and Steven M. Naidich, both of eGenomics, Inc.

The Company has engaged Popper and Company LLC (http://www.popperandco.com) to assist with its commercialization activities.


'/>"/>
SOURCE eGenomics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. Mirus Bio Awarded Grants & Contracts of Over $5 Million
3. ICx Awarded $1.5 M Contract by Department of Homeland Security for Development of Next Generation Bio Aerosol Systems
4. ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS
5. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
8. Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics
9. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
10. Implicit Awarded US $16.3 Million U.S. Government Contract to Develop Immunomodulatory Drug for Biodefense Threats
11. BIO-key(R) Awarded Contract to Deploy Incident Reporting System for Littleton, CO Police Department
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)...  Sequenom, Inc. (NASDAQ: SQNM ), a ... the development of innovative products and services, announced today ... States denied its petition to review decisions ... U.S. Patent No. 6,258,540 (",540 Patent") are not patent ... Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories decision.  ...
(Date:6/27/2016)... ... 27, 2016 , ... Parallel 6 , the leading software as a ... Reach Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine ... team. , Using the CONSULT module, patients and physicians can schedule a face to ...
(Date:6/27/2016)... , ... June 27, 2016 , ... ... for Amgen, will join the faculty of the University of North Carolina ... professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:5/24/2016)... Calif. , May 24, 2016 Ampronix facilitates superior patient care by ... LMD3251MT  3D medical LCD display is the latest premium product recently added to the ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
Breaking Biology News(10 mins):